Alzheimer’s News Renews Investor Interest in Biotech
June 7, 2021
Recent approval by U.S. regulators of a drug to treat Alzheimer’s disease (Aducanumab) lifted shares of companies developing treatments for the mind wasting disease. Our Kevin Gade told Reuter’s News, “The biotech sector needed a spark and this was an explosion.”
Kevin T. Gade, CFA, CFP
Read the full article HERE (a subscription may be required).